2.73

8.76% +0.22

Armata Pharmaceuticals Inc (ARMP)

Overview News Price History Option Chain Discussions Forecast Stock Split

Armata Pharmaceuticals Inc stock is currently priced at $2.73, with a 24-hour trading volume of 3,674. It has seen a +8.76% increased in the last 24 hours and a -27.78% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $2.60 pivot point. If it approaches the $2.87 resistance level, significant changes may occur.

Previous Close:

$2.51

Open:

$2.74

24h Volume:

3,674

Market Cap:

$90.73M

Revenue:

Net Income/Loss:

$-59.51M

P/E Ratio:

-2.4818

EPS:

-1.1

Net Cash Flow:

$-55.09M

1W Performance:

+7.06%

1M Performance:

-27.78%

6M Performance:

+14.23%

1Y Performance:

+84.46%

1D Range:

$2.55

$2.74

52W Range:

$1.0701

$5.2565

Armata Pharmaceuticals Inc Stock (ARMP) Company Profile

Name

Armata Pharmaceuticals Inc

Sector

Healthcare (1216)

Industry

Biotechnology (700)

Phone

310-655-2928

Address

4503 Glencoe Avenue, Marina del Rey, CA

Employee

Twitter

Next Earnings Date

2024-05-09

Latest SEC Filings

ARMP's Discussions on Twitter

Armata Pharmaceuticals Inc Stock (ARMP) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-19-19	Initiated	Ladenburg Thalmann	Buy

Armata Pharmaceuticals Inc Stock (ARMP) Latest News

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Lags Revenue Estimates

Zacks Investment Research

Armata Pharmaceuticals Inc Stock (ARMP) Financials Data

Armata Pharmaceuticals Inc (ARMP) Net Income 2024

ARMP net income (TTM) was -$59.51 million for the quarter ending September 30, 2023, a -82.27% decrease year-over-year.

Armata Pharmaceuticals Inc (ARMP) Cash Flow 2024

ARMP recorded a free cash flow (TTM) of -$55.09 million for the quarter ending September 30, 2023, a -64.51% decrease year-over-year.

Armata Pharmaceuticals Inc (ARMP) Earnings per Share 2024

ARMP earnings per share (TTM) was -$1.72 for the quarter ending September 30, 2023, a -66.99% decline year-over-year.

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections in the United States. The company develops its products using its proprietary bacteriophage-based technology. Its product candidate is the AP-SA01 that targets Staphylococcus aureus, including multidrug-resistant strains. The company is also developing and advancing synthetic phage for treating diseases caused by pseudomonas aeruginosa. Armata Pharmaceuticals, Inc. is headquartered in Marina del Rey, California.